PBK M2101
Alternative Names: PBK-M2101; PBK_M2101Latest Information Update: 17 Aug 2023
At a glance
- Originator Pharmbio Korea
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Gastrointestinal disorders
Most Recent Events
- 28 Jun 2023 Phase-III clinical trials in Gastrointestinal disorders in South Korea (unspecified route) (NCT05923918)
- 13 Jun 2023 Pharmbio Korea receives approval from Ministry of Food and Drug Safety in South Korea for initiation of phase III trial in Colonic disorders ()
- 28 Feb 2023 Pharmbio Korea receives approval to initiate clinical trial for the treatment of Gastrointestinal disorders